Oncology Topic Homepage

Prostate Cancer Learning Hub

,Prostate Cancer Learning Hub

Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.

The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer. In addition access to editorials of key journal publications, an events calendar, video channel, patient materials and interactive healthcare professionals tools are also available.

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
  2. Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.

     

Soft Tissue Sarcoma

Soft Tissue Sarcoma

Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.

Management of soft tissue sarcoma depends on the stage of disease and histological subtype.1 Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy, uses high energy rays to help cure cancers, is also often administered for patients in whom surgery is inappropriate or who decline surgery.1

For soft tissue sarcomas, the specialist healthcare professional may recommend radiotherapy to shrink sarcomas before surgery, help stop the sarcoma returning after surgery, to help slow the growth rate of advanced sarcomas and help relieve symptoms.

Discover classification of sarcomas by histopathology, look at prevalence and more by visiting the The Soft Tissue Sarcoma Knowledge Centre.


References

  1. . Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.

Clinical Case Studies

Pulmonary Nodules

Respiratory Medicine & Allergy: Lung Cancer

Burhan Khan, Consultant Respiratory Physician, Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford, Kent, UK
Richard Leach, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust , London, UK

Case History
51-year-old man presented with a six-month history of paroxysmal cough following a viral upper respiratory tract infection. Apart from an episode of pneumonia as a child he had no other significant medical history, no allergies and he was on no medications.

Hypersensitivity Pneumonitis

Respiratory Medicine & Allergy: Non granuloma interstitial lung disease

Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Boris Lams, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK

Case History
A 49-year-old Cypriot woman was referred with a nine-month history of gradually increasing breathlessness and a dry cough. She was breathless at 100 yards.

Medical Videos

Surviving Advanced Breast Cancer
Surviving Advanced Breast Cancer
Eribulin Trial Success
Eribulin Trial Success
Metastatic Breast Cancer - A Patient's View of Various Treatments Including Eribulin
Metastatic Breast Cancer - A Patient's View of Various Treatments Including Eribulin
New Developments in the Treatment of Breast Cancer
New Developments in the Treatment of Breast Cancer
In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
An Overview of Pancreatic NET and the Available Treatments
An Overview of Pancreatic NET and the Available Treatments
HPV Vaccine
HPV Vaccine
Cancer Vaccines- Dr. Kelvin Lee
Cancer Vaccines- Dr. Kelvin Lee
An Animation Explaining the Development of Lymphoma
An Animation Explaining the Development of Lymphoma

Recent Drug Updates

Medical Journal Abstracts on Oncology

Metformin, cancer and glucose metabolism

yesterday -  Endocrine-Related Cancer

Metformin is the first-line treatment for type 2 Diabetes. Several clinical studies have reported that type 2 diabetic Patients treated with metformin might have a lower cancer risk. One of the ...

Electronic cigarette use among patients with cancer: Characteristics of electronic cigarette users and their smoking cessation outcomes

10 days ago -  Cancer

Background: Given that continued smoking after a cancer diagnosis increases the risk of adverse health outcomes, patients with cancer are strongly advised to quit. Despite a current lack of ...

Medical Images

Hematoxylin and eosin stain
Hematoxylin and eosin stain
Bronchogenic cyst
Bronchogenic cyst
Amiodarone Pulmonary Toxicity
Amiodarone Pulmonary Toxicity
Hypersensitivity Pneumonitis
Hypersensitivity Pneumonitis
Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer (SCLC)
Sarcoidosis - radiograph showing interstitial shadowing
Sarcoidosis - radiograph showing interstitial shadowing
Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Pulmonary nodule
Pulmonary nodule
Sarcoidosis - chest radiograph
Sarcoidosis - chest radiograph

Online CME

Clinical Review - Breast Cancer

This activity covers the aetiology, diagnosis and management of breast cancer.

No Blunting of Immunologic Response to Sipuleucel-T When Combined With Abiraterone Acetate Plus Prednisone in mCRPC

After participating in this activity, clinicians should be better able to: Describe the differences in immunologic end points between concurrent sipuleucel-T and abiraterone as compared with the sequential use of...

mCRPC: The Right Treatment for the Right Patient at the Right Time

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists and urologists involved in the treatment of patients with metastatic prostate cancer. The goal of...

Clinical Trials

Modufolin® in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin in Colorectal Cancer

17-09-2014

The purpose of this clinical study is to investigate 3 doses of Modufolin to identify the best dose for further assessment. The purpose is also to characterise the tolerability of Modufolin in combination with 5-FU (in Part 1) and in combination with..

... 5-FU and Oxaliplatin (in Part 2).

State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study (ROCOCO)

15-09-2014

Given that the cost of proton therapy is considerably higher than that of conventional radiotherapy with photons, it is necessary to establish whether these higher costs are worthwhile in light of the expected advantages2,3,4. Thus, clear evidence of..

... the situations in which proton therapy outperforms conventional photon treatment is needed. The investigators therefore aim to demonstrate through an in silico trial that proton therapy decrease the amount of irradiated normal tissue and, consequently, the risk of side effects in the surrounding normal tissue as well as the risk of secondary tumors. The same overall treatment time and an equal number of fractions will be used for both treatment modalities wherever possible. The most optimal technique for each individual patient, based on objective criteria related to limiting dose to normal tissue, will be prescribed by the institution concerned for each treatment option.

Back to top